XOMA (NASDAQ:XOMA) Downgraded by StockNews.com to “Sell”

XOMA (NASDAQ:XOMA) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Tuesday.

Separately, HC Wainwright cut their price objective on shares of XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research report on Monday, February 3rd.

XOMA Trading Down 1.8 %

XOMA stock traded down $0.43 during midday trading on Tuesday, hitting $23.10. 25,808 shares of the stock were exchanged, compared to its average volume of 47,531. XOMA has a fifty-two week low of $21.27 and a fifty-two week high of $35.00. The stock has a market capitalization of $272.19 million, a price-to-earnings ratio of -6.64 and a beta of 0.90. The stock’s 50-day simple moving average is $26.13 and its 200 day simple moving average is $28.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

Insider Buying and Selling

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 7.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On XOMA

A number of institutional investors have recently made changes to their positions in XOMA. Woodline Partners LP increased its position in shares of XOMA by 63.9% during the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock valued at $4,107,000 after acquiring an additional 60,927 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of XOMA by 238.9% in the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock valued at $318,000 after purchasing an additional 8,522 shares in the last quarter. Barclays PLC grew its holdings in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of XOMA in the fourth quarter valued at approximately $206,000. Finally, Renaissance Technologies LLC grew its holdings in shares of XOMA by 89.8% in the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 7,619 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.